AURIEL ‐PsO: a randomized, double‐blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB 11022 to reference adalimumab in patients with moderate‐to‐severe chronic plaque‐type psoriasis-Reference-Cited by-同舟云学术

AURIEL ‐PsO: a randomized, double‐blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB 11022 to reference adalimumab in patients with moderate‐to‐severe chronic plaque‐type psoriasis

Published:2019-09-26 Issue:2 Volume:182 Page:316-326
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Hercogová J.¹,Papp K.A.²^ORCID,Chyrok V.³,Ullmann M.³,Vlachos P.⁴,Edwards C.J.⁵

Affiliation:

1. Dermatology Department 2nd Medical Faculty Charles University and Na Bulovce Hospital Prague Czech Republic

2. K Papp Clinical Research and Probity Medical Research Inc. Waterloo ON Canada

3. Fresenius Kabi Eysin Switzerland

4. Cytel Geneva Switzerland

5. NIHR Clinical Research Facility University of Southampton Southampton U.K.

Funder

Merck

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.18220

Reference47 articles.

1. Anti-TNF Therapy, from Rationale to Standard of Care: What Lessons Has It Taught Us?

2. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor

3. Adalimumab in the Treatment of Immune-Mediated Diseases

4. Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth?

5. Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A randomized, double-blind, phase III study assessing clinical similarity of SB17 (proposed ustekinumab biosimilar) to reference ustekinumab in subjects with moderate-to-severe plaque psoriasis;Journal of the American Academy of Dermatology;2024-09

2. Modelling the opportunity for cost-savings or patient access with biosimilar adalimumab and tocilizumab: a European perspective;Journal of Medical Economics;2024-07-23

3. Clinical outcomes of switching to adalimumab biosimilar (MSB11022) in patients with rheumatoid arthritis: RESTART Spanish Registry;Current Medical Research and Opinion;2024-07-04

4. Effectiveness and safety of adalimumab biosimilar in patients with inflammatory bowel disease;Farmacia Hospitalaria;2024-04

5. Persistence and safety of anti-TNF biosimilars versus originators in immune-mediated inflammatory diseases: an observational study on the French National Health Data System;RMD Open;2024-03